Drug Search Results
More Filters [+]

Refametinib

Alternative Names: refametinib, rdea119, bay86-9766, bay86 9766, bay869766, bay86-9766, bay869766, bay86 9766
Latest Update: 2024-03-23
Latest Update Note: PubMed Publication

Product Description

Refametinib potently inhibits MEK1/2, part of the MAPK signaling pathway. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27975152/)

Mechanisms of Action: MAP2K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Refametinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatocellular Carcinoma|Oncology Unspecified|Colorectal Cancer|Biliary Tract Cancer|Adenocarcinoma

Phase 1: Colorectal Cancer|Oncology Solid Tumor Unspecified|Lung Cancer|Breast Cancer|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ARES

P2

Active, not recruiting

Colorectal Cancer

2017-09-26

Refametinib in combination with sorafenib in RAS mutant HCC

P2

Completed

Hepatocellular Carcinoma

2017-03-13

JapicCTI-132357

P2

Completed

Hepatocellular Carcinoma

2016-12-31

JapicCTI-142425

P2

Completed

Hepatocellular Carcinoma

2016-12-31

Recent News Events